HONG KONG, Nov. 17, 2025 /PRNewswire/ -- The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical - they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region.
Co-organized by the Hong Kong Precision Oncology Society, The Hong Kong Polytechnic University, the Hong Kong Integrated Oncology Centre, the Artificial Intelligence Association of Hong Kong, and supported by Gene Solutions and the K-CONNECT Platform - the event brought together 13 distinguished faculty leaders and more than 150 oncologists, molecular researchers, and AI scientists. Hosted at the iconic Hotel ICON Hong Kong, the program highlighted clinically validated technologies already in deployment across Asia, signaling a new era of scalable, AI-powered precision oncology.
Why do AI and Multi-omics Matter?
Multi-omics integrates diverse layers of biological data—such as DNA fragments, methylation patterns, copy number aberrations, and genetic mutations—to provide a more comprehensive view of cancer cells, not only found in tissue but also in blood samples. When harnessed with AI, these insights enable rapid, accurate analysis, empowering clinicians to detect cancer earlier, tailor personalized treatments, and monitor disease progression with unprecedented precision.
Early Detection
In the opening session on AI and multi-omics for cancer screening and diagnostics, Dr. Le Son Tran, Principal Investigator at Gene Solutions, explained the role of advanced multi-omics data and multi-modal AI algorithms in SPOT-MAS, a next-generation Multi-Cancer Early Detection (MCED) blood test already accessible across APAC:
"Our AI models were trained on a large multi-omics dataset and validated in large-scale, multicenter studies to detect circulating tumor DNA (ctDNA) signals and accurately identify their tissue of origin. This enables the test to screen for up to 75 cancer types and subtypes with 78% sensitivity and 99% specificity—all from a single, affordable blood draw."
Building on this, Prof. Zhang Wei Xiong from The Hong Kong Polytechnic University shared his lab's discovery of non-canonical circular RNAs, a new type of RNA biomarker with stable expression in blood, representing another potential "omics" in early cancer screening.
Drawing from clinical practice, Dr. Brendan Chia Seng Hup, Senior Consultant Radiation Oncologist at Raffles Medical Group added:
"With Multi-Cancer Early Detection tests, we get cancer tissue-of-origin information and high sensitivity, giving us a more targeted direction for diagnostic follow-up. The improved affordability enables broader adoption without compromising accuracy."
Personalized Treatment
Although many targeted therapies and immunotherapies are currently approved, tumor genomic changes remain highly complex, and clinicians require comprehensive insights to tailor personalized treatment strategies.
Subsequent sessions delved into the role multi-omics in comprehensive genomic profiling (CGP) and transcriptomic profiling (CGTP), emphasizing how deep-learning models and multidisciplinary Molecular Tumor Boards (MTBs) translate complex genomic findings into actionable treatment plans.
Dr. Joseph Siu-Kie Au, President of the Hong Kong Precision Oncology Society, emphasized:
"AI will serve as the orchestrator, fusing multi-omics, clinical history, and imaging into actionable insights."
Prof. Aya Helali from Queen Mary Hospital reinforced the value of comprehensive genomic profiling to provide clinically relevant information on a patient's cancer to enable more personalized and timely interventions for each patient and the role of Molecular Tumor Boards:
"Cancer is not a single disease. Molecular Tumor Boards help us interpret complex genetic results and craft individualized treatment plans."
Continuous Monitoring
Circulating tumor DNA (ctDNA) is also a key biomarker for cancer monitoring. ctDNA monitoring for molecular residual disease (MRD) is driving global attention among oncologists. Dr. Terence Aik Huang Tan, Senior Consultant Medical Oncologist at Raffles Medical Group, shared about clinical guidelines and practical real-world considerations on when to use ctDNA-MRD technology:
"We no longer need to debate sensitivity or specificity—the data is strong. The real question now is where and how to use it in practice." He demonstrated this through interactive case studies and live polling—nearly 100% of participants agreed that ctDNA-MRD monitoring should be part of shared decision-making, signaling a major shift in clinical mindset.
Dr. Ye Gang from Foshan Fosun Chancheng Hospital added:
"Like an iceberg, ctDNA helps us detect what's hidden below the surface. I believe that MRD-guided care will improve patient outcomes- we now need more real-world data."
Gene Solutions introduced K-TRACK and K-4CARE, validated platforms combining genomic and transcriptomic profiling with ctDNA-based MRD monitoring. These solutions enable longitudinal tracking of treatment response and recurrence risk, helping clinicians personalize care in real time.
Dr. Nguyen Duy Sinh, Oncology Medical Director at Gene Solutions, explained the uniqueness of these platforms: "Integrating both genomic and transcriptomic data helps clinicians explore greater potential for identifying suitable treatments. Moreover, the multi-omics application in ctDNA-MRD monitoring has demonstrated better performance in our study compared to previous single-dimensional approaches."
The Bigger Picture
The conference culminated in a forward-looking session on AI and multi-omics integration, with a unified call for collaboration:
"AI will fundamentally change cancer care—shifting from reactive to proactive," said Prof. Cai Jing from the Hong Kong Polytechnic University.
Dr. Joseph Siu-Kie Au added, "We must build an ecosystem across APAC to accelerate AI model training and make advanced cancer management accessible."
Dr. Lawrence Luk Lung, from the Artificial Intelligence Association of Hong Kong concluded, "Collaboration is key - bringing together medical experts, AI specialists, and regulators to make real progress."
By combining AI and multi-omics, healthcare systems can deliver earlier diagnoses, smarter treatments, and better survival outcomes—making precision oncology accessible to all.
Find out the highlight takeaways from the APAC Precision Oncology Conference 2025: https://genesolutions.com/news/highlight-takeaways-from-the-apac-precision-oncology-conference-2025/
About APAC Precision Oncology Conference
The conference drives transformation in cancer care across Asia-Pacific by uniting AI and multi-omics innovations, fostering cross-border collaboration, and accelerating precision oncology adoption.
More info: https://apacprecisiononcology.com
About K-CONNECT Platform
A collaborative initiative bridging technology and clinical practice to unlock ctDNA-MRD's potential for personalized oncology.
More info: https://kconnect.genesolutions.com
About Gene Solutions
Gene Solutions is an international biotechnology company, driving advancements in genetic testing and research innovation. By integrating Next-Generation Sequencing (NGS) and Artificial Intelligence, the company offers a comprehensive portfolio of advanced solutions, including:
- Reproductive Health: Next-generation Non-invasive Prenatal Testing (NIPT), which covers both fetal abnormalities and maternal health indicators.
- Clinical Oncology:
- Multi-cancer Screening using multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization.
- Comprehensive Genomic and Transcriptomic Profiling (CGTP) combined with clinically validated ctDNA-based molecular residual disease (MRD) monitoring to guide precision treatment and track disease progression.
As of 2025, Gene Solutions has delivered over three million genetic tests worldwide, supported by proprietary research, CAP-accredited laboratories, and a commitment to advancing precision medicine through clinical studies, technology development, and global collaborations.
Find more information at https://genesolutions.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
- Company named "Best Financially Managed Semiconductor Company (Achieving Greater than $1 Billion in Annual Sales)" and "Outstanding Asia-Pacific Semiconductor Company" simultaneously
- Accelerates recovery from market downturn leveraging world-class HBM leadership; Global management performance recognized
- Reflects company's technology leadership and customer-centric execution
- SK Chairman Chey Tae-won emphasizes: "Technological competitiveness must remain unwavering in challenging times"
- Commits to driving new customer value and leading global AI market growth as a "Full-Stack AI Memory Creator"
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has been named the winner of the Best Financially Managed Semiconductor Company Award (Achieving Greater than $1 Billion in Annual Sales)[1] and the Outstanding Asia-Pacific Semiconductor Company Award[2] at the Global Semiconductor Alliance (GSA)[3] Awards 2025, held on December 4 PST in Santa Clara, California.
| [1]The Best Financially Managed Semiconductor Company Award: A category recognizing public semiconductor companies based on financial soundness and operational efficiency. Awards are presented in two categories — annual sales over $1 billion and annual sales under $1 billion — and are considered among the most authoritative honors in the global semiconductor industry. |
| [2]Outstanding Asia-Pacific Semiconductor Company Award: A special category recognizing semiconductor companies headquartered in the Asia-Pacific region based on comprehensive evaluations including product excellence, business vision, leadership, and market success. |
| [3]GSA(Global Semiconductor Alliance): A global CEO-level semiconductor organization serving as a hub for technological information sharing across more than 25 countries and over 250 corporate members. |
The GSA Awards, organized annually since 1996, are regarded as the most prestigious honors in the global semiconductor sector, recognizing outstanding performance in leadership, financial results and industry reputation. SK hynix secured its second win in the financial management category following 2017, and its first recognition as the top Asia-Pacific semiconductor company. The dual achievement reinforces the company's reputation as a leading global technology innovator.
While the semiconductor industry faced a severe downturn just two years ago, the company has been the fastest to rebound thanks to its advanced AI memory technologies including HBM. This performance has resulted in global recognition for its operational excellence and financial execution. SK hynix plans to continue building sustainable growth with its dominant leadership in the AI memory market.
The awards reflect the company's proactive delivery of groundbreaking HBM solutions and its steadfast commitment to customer-centric performance in surging global AI demand. SK Chairman Chey Tae-won has consistently emphasized that securing technological competitiveness must remain unwavering, especially during challenging times. This long-term focus on technology investment and global cooperation network has contributed to the company's improved performance and reinforced financial health.
Driven by this strategy, SK hynix has recorded historic performance throughout 2025. For the first three quarters, the company reported revenue of 64 trillion won and operating profit of 28 trillion won in total, positioning it well to surpass its previous full-year earnings record set in 2024 (66 trillion won in revenue and 23 trillion won in operating profit).
Financial health has also significantly strengthened. As of the end of the third quarter, cash and cash equivalents reached 27.9 trillion won, up 10.9 trillion won quarter-over-quarter, while interest bearing debt decreased to 24.1 trillion won— successfully transitioning into a net cash position of approximately 4 trillion won.
To secure long-term leadership in AI memory, SK hynix is accelerating major investments. The Cheongju M15X fab, which opened its cleanroom earlier than planned in October, is on track to begin HBM mass production in the first half of next year. Construction of the first fab in the Yongin Semiconductor Cluster, launched in February, is also progressing ahead of schedule.
With its recent financial achievements and continued expansion, SK hynix is expected to further solidify its AI memory leadership going forward.
SK hynix was represented at the ceremony by Justin Kim, President & Head of AI Infra at SK hynix, and Sungsoo Ryu, President of SK hynix America. "It is a great honor to receive this award." Kim said, "We will continue to lead the market and create new value for customers as a Full-Stack AI Memory Creator, driving growth across the global AI ecosystem."
About SK hynix Inc.
SK hynix Inc., headquartered in Korea, is the world's top tier semiconductor supplier offering Dynamic Random Access Memory chips ("DRAM") and flash memory chips ("NAND flash") for a wide range of distinguished customers globally. The Company's shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has been named the winner of the Best Financially Managed Semiconductor Company Award (Achieving Greater than $1 Billion in Annual Sales)[1] and the Outstanding Asia-Pacific Semiconductor Company Award[2] at the Global Semiconductor Alliance (GSA)[3] Awards 2025, held on December 4 PST in Santa Clara, California.
| [1]The Best Financially Managed Semiconductor Company Award: A category recognizing public semiconductor companies based on financial soundness and operational efficiency. Awards are presented in two categories — annual sales over $1 billion and annual sales under $1 billion — and are considered among the most authoritative honors in the global semiconductor industry. |
| [2]Outstanding Asia-Pacific Semiconductor Company Award: A special category recognizing semiconductor companies headquartered in the Asia-Pacific region based on comprehensive evaluations including product excellence, business vision, leadership, and market success. |
| [3]GSA(Global Semiconductor Alliance): A global CEO-level semiconductor organization serving as a hub for technological information sharing across more than 25 countries and over 250 corporate members. |
[1]The Best Financially Managed Semiconductor Company Award: A category recognizing public semiconductor companies based on financial soundness and operational efficiency. Awards are presented in two categories — annual sales over $1 billion and annual sales under $1 billion — and are considered among the most authoritative honors in the global semiconductor industry.
[2]Outstanding Asia-Pacific Semiconductor Company Award: A special category recognizing semiconductor companies headquartered in the Asia-Pacific region based on comprehensive evaluations including product excellence, business vision, leadership, and market success.
[3]GSA(Global Semiconductor Alliance): A global CEO-level semiconductor organization serving as a hub for technological information sharing across more than 25 countries and over 250 corporate members.
The GSA Awards, organized annually since 1996, are regarded as the most prestigious honors in the global semiconductor sector, recognizing outstanding performance in leadership, financial results and industry reputation. SK hynix secured its second win in the financial management category following 2017, and its first recognition as the top Asia-Pacific semiconductor company. The dual achievement reinforces the company's reputation as a leading global technology innovator.
While the semiconductor industry faced a severe downturn just two years ago, the company has been the fastest to rebound thanks to its advanced AI memory technologies including HBM. This performance has resulted in global recognition for its operational excellence and financial execution. SK hynix plans to continue building sustainable growth with its dominant leadership in the AI memory market.
The awards reflect the company's proactive delivery of groundbreaking HBM solutions and its steadfast commitment to customer-centric performance in surging global AI demand. SK Chairman Chey Tae-won has consistently emphasized that securing technological competitiveness must remain unwavering, especially during challenging times. This long-term focus on technology investment and global cooperation network has contributed to the company's improved performance and reinforced financial health.
Driven by this strategy, SK hynix has recorded historic performance throughout 2025. For the first three quarters, the company reported revenue of 64 trillion won and operating profit of 28 trillion won in total, positioning it well to surpass its previous full-year earnings record set in 2024 (66 trillion won in revenue and 23 trillion won in operating profit).
Financial health has also significantly strengthened. As of the end of the third quarter, cash and cash equivalents reached 27.9 trillion won, up 10.9 trillion won quarter-over-quarter, while interest bearing debt decreased to 24.1 trillion won— successfully transitioning into a net cash position of approximately 4 trillion won.
To secure long-term leadership in AI memory, SK hynix is accelerating major investments. The Cheongju M15X fab, which opened its cleanroom earlier than planned in October, is on track to begin HBM mass production in the first half of next year. Construction of the first fab in the Yongin Semiconductor Cluster, launched in February, is also progressing ahead of schedule.
With its recent financial achievements and continued expansion, SK hynix is expected to further solidify its AI memory leadership going forward.
SK hynix was represented at the ceremony by Justin Kim, President & Head of AI Infra at SK hynix, and Sungsoo Ryu, President of SK hynix America. "It is a great honor to receive this award." Kim said, "We will continue to lead the market and create new value for customers as a Full-Stack AI Memory Creator, driving growth across the global AI ecosystem."
About SK hynix Inc.
SK hynix Inc., headquartered in Korea, is the world's top tier semiconductor supplier offering Dynamic Random Access Memory chips ("DRAM") and flash memory chips ("NAND flash") for a wide range of distinguished customers globally. The Company's shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SK hynix Honored with Two Major Titles at GSA Awards 2025
